Tracey Sunderland
Director de Operaciones en CoDa Therapeutics (NZ) Ltd. .
Perfil
Tracey Sunderland is currently the Chief Operating Officer at OcuNexus Therapeutics, Inc. and CoDa Therapeutics (NZ) Ltd.
She previously worked as a Quality Manager at Protemix Corp.
Ltd.
and as a Principal at Auckland Healthcare Services Ltd.
Sunderland received an undergraduate degree from Auckland University of Technology.
Cargos activos de Tracey Sunderland
Empresas | Cargo | Inicio |
---|---|---|
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | Director de Operaciones | 01/10/2006 |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Director de Operaciones | 25/03/2010 |
Antiguos cargos conocidos de Tracey Sunderland.
Empresas | Cargo | Fin |
---|---|---|
Auckland Healthcare Services Ltd.
Auckland Healthcare Services Ltd. Hospital/Nursing ManagementHealth Services Auckland Healthcare Services Ltd. operates tertiary hospitals that provide mental health services. | Corporate Officer/Principal | - |
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | Corporate Officer/Principal | - |
Formación de Tracey Sunderland.
Auckland University of Technology | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 4 |
---|---|
Protemix Corp. Ltd.
Protemix Corp. Ltd. Pharmaceuticals: MajorHealth Technology Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held. | Health Technology |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Health Technology |
Auckland Healthcare Services Ltd.
Auckland Healthcare Services Ltd. Hospital/Nursing ManagementHealth Services Auckland Healthcare Services Ltd. operates tertiary hospitals that provide mental health services. | Health Services |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | Health Technology |
- Bolsa de valores
- Insiders
- Tracey Sunderland